Gufic Biosciences Limited (NSE:GUFICBIO)
345.35
-3.55 (-1.02%)
Jul 4, 2025, 3:29 PM IST
Gufic Biosciences Revenue
In the fiscal year ending March 31, 2025, Gufic Biosciences had annual revenue of 8.20B INR with 1.63% growth. Gufic Biosciences had revenue of 2.05B in the quarter ending March 31, 2025, with 5.14% growth.
Revenue
8.20B
Revenue Growth
+1.63%
P/S Ratio
4.24
Revenue / Employee
5.50M
Employees
1,491
Market Cap
34.74B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 8.20B | 131.40M | 1.63% |
Mar 31, 2024 | 8.07B | 1.16B | 16.80% |
Mar 31, 2023 | 6.91B | -885.35M | -11.36% |
Mar 31, 2022 | 7.79B | 2.91B | 59.76% |
Mar 31, 2021 | 4.88B | 1.09B | 28.74% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sun Pharmaceutical Industries | 525.78B |
Divi's Laboratories | 93.60B |
Cipla | 272.67B |
Apollo Hospitals Enterprise | 217.94B |
Zydus Lifesciences | 232.42B |
Mankind Pharma | 122.07B |
Aurobindo Pharma | 317.24B |
Fortis Healthcare | 77.83B |
Gufic Biosciences News
- 4 months ago - Gufic Biosciences Ltd (BOM:509079) Q3 2025 Earnings Call Highlights: Navigating Profitability ... - GuruFocus
- 4 months ago - Q3 2025 Gufic Biosciences Ltd Earnings Call Transcript - GuruFocus